RT @Yuz6Yusof: Novel target (IL23-i; Guselkumab) in treating TNF-IR #psoriaticarthritis. Dr Coates presented results fro
Tweet Content
Novel target (IL23-i; Guselkumab) in treating TNF-IR #psoriaticarthritis. Dr Coates presented results from Phase III COSMOS. 44.4% of GUS-treated vs 19.8% Placebo-tx achieved ACR20 response at Wk24 (p<0.001). Well tolerated and No major safety #EULAR2021 #OP0230 @RheumNow https://t.co/EuGaacSuxF
Show on Archive Page
On
Display in Search Results
On
PDQ
Off